X‐Linked Inhibitor of Apoptosis Protein (XIAP) Contributes to ERK1/2‐Mediated Anoikis Resistance in Hepatocellular Carcinoma
MedComm – Oncology · 2026-03 · 5 (1)
DOI: 10.1002/mog2.70059 ↗Kurz gefasst
Fachartikel in der Zeitschrift MedComm – Oncology, online erschienen am 25.03.2026. Verfasst von Qingyu Zeng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing, China. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Natural Science Foundation of China, National Institutes of Health.
Abstract (Originalsprache)
X‐linked inhibitor of apoptosis protein (XIAP) is a multifunctional protein that regulates many cellular functions. Anoikis resistance is necessary for hepatocellular carcinoma (HCC) intrahepatic spread and extrahepatic metastasis. However, limited information is available regarding the mechanism of XIAP underlying the resistance of HCC cells to anoikis. Here we show an increased expression of XIAP in microvascular tumor thrombosis (MVTT) of HCC, which is positively correlated with the expression of extracellular signal‐regulated kinases 1/2 (ERK1/2). HCC cells exhibit an increase in XIAP expression when detached, leading to their resistance to anoikis. Furthermore, enhanced phosphorylation of XIAP promotes resistance to anoikis in HCC cells. In addition, the zinc‐binding baculovirus IAP repeat (BIR) domains of XIAP, instead of the highly intriguing novel gene (RING) domain, are responsible for conferring resistance to anoikis in HCC cells. Importantly, our findings indicate that ERK1/2 can control the expression of XIAP, leading to the resistance of HCC to anoikis in cell‐based and mouse models. The significance of the interaction between XIAP and ERK1/2 in resisting anoikis is emphasized by our discoveries, presenting novel avenues for HCC treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing, China.
- Institute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
- Department of Hepatobiliary Surgery, Northern Jiangsu People's Hospital, Yangzhou, China.
- Research Institute of General Surgery, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.
- Clinical Laboratory, Xuzhou Central Hospital, Southeast University Affiliated Xuzhou Central Hospital, Xuzhou, China.
- Department of Pathology, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou, China.
ORCID-Profile: Qingyu Zeng, Zhaoji Pan
Förderung
- NCI NIH HHS
- National Natural Science Foundation of China
- National Institutes of Health
- American Cancer Society
Zitieren
APA
Zeng, Q., Mao, Z., Sun, S., Gao, Z., Mu, J., Pan, Z., Li, Q., Mao, X., Xu, J., Bai, D., Huang, S., & Chen, L. (2026). X‐Linked Inhibitor of Apoptosis Protein (XIAP) Contributes to ERK1/2‐Mediated Anoikis Resistance in Hepatocellular Carcinoma. MedComm – Oncology, 5(1). https://doi.org/10.1002/mog2.70059
Vancouver
Zeng Q, Mao Z, Sun S, Gao Z, Mu J, Pan Z, et al. X‐Linked Inhibitor of Apoptosis Protein (XIAP) Contributes to ERK1/2‐Mediated Anoikis Resistance in Hepatocellular Carcinoma. MedComm – Oncology. 2026;5(1). doi:10.1002/mog2.70059
BibTeX
@article{Zeng2026,
author = {Zeng, Qingyu and Mao, Zun and Sun, Sumin and Gao, Zhixiang and Mu, Junpeng and Pan, Zhaoji and Li, Qing and Mao, Xueyuan and Xu, Jianbo and Bai, Dousheng and Huang, Shile and Chen, Long},
title = {X‐Linked Inhibitor of Apoptosis Protein (XIAP) Contributes to ERK1/2‐Mediated Anoikis Resistance in Hepatocellular Carcinoma},
journal = {MedComm – Oncology},
year = {2026},
volume = {5},
number = {1},
doi = {10.1002/mog2.70059}
}
EUVIMED